Atrial fibrillation and efficacy of semaglutide 2.4 mg in obesity-related HFpEF: A Patient Level Pooled analysis of STEP-HFpEF and STEP-HFpEF DM trials

30 August 2024 (08:00 - 17:30)

Organised by:

Sign in for access options

Sign in for access options

About the speaker

Doctor Mikhail Kosiborod

St. Luke's Mid America Heart Institute, Kansas City (United States of America)

7 More presentations in this session

Presentation thumbnail

Inflammation in obesity-related HFpEF: the STEP-HFpEF programme

Professor S. Verma (Toronto, CA)

Presentation thumbnail

STEP-HFpEF Program Echocardiography Substudy

Professor S. Solomon (Boston, US)

Presentation thumbnail

Effects of the GLP-1 receptor agonist, semaglutide, on heart failure outcomes: a pre-specified analysis of the FLOW trial in participants with type 2 diabetes and chronic kidney disease

Doctor R. Pratley (Orlando, US)

Presentation thumbnail

Effects of semaglutide on clinical events in heart failure with preserved ejection fraction: a pooled, participant-level analysis of SELECT, FLOW, STEP-HFpEF and STEP-HFpEF DM trials

Doctor M. Kosiborod (Kansas City, US)

Presentation thumbnail

Semaglutide and cardiovascular outcomes in females with overweight and obesity: A prespecified analysis of the SELECT trial

Professor S. Verma (Toronto, CA)

Access the full session

Session thumbnail

Clinical trial updates on the GLP-1 receptor agonist, semaglutide

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024

You may be interested in

Congress Presentation

Obesity as a risk factor for heart failure and impact on outcomes

Congress Presentation

Management of obesity in cardiac patients: what cardiologists should know

Congress Presentation

ESC Clinical Consensus Statement on Obesity and Cardiovascular Disease - discussion

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources